Skip to content
2000
Volume 15, Issue 6
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The pharmacotherapy of complex pathological states at the cardiovascular level often requires different and complementary pharmacodynamic properties. This is frequently achieved through the administration of “cocktails”, composed by several drugs possessing different mechanisms of action. In the last years, a revision of the “one-compound-onetarget” paradigm led to a wide development of new classes of molecules, possessing more pharmacological targets. Among them, this innovative strategy produced interesting hybrid drugs, with a dual mechanism of action: a) a fundamental and well-established pharmacodynamic profile and b) the release of nitric oxide (NO), playing a pivotal role in the modulation of the function of cardiovascular system, where it induces vasorelaxing and antiplatelet responses. These new pharmacodynamic hybrids present the advantage of adding to a main mechanism of action (for example, cyclooxygenase inhibition, beta-antagonism or ACE-inhibition) also a slow release of NO, useful either to reduce the adverse side effects and/or to improve the effectiveness of the drug. This review presents the chemical features of many examples of NO-releasing hybrids of cardiovascular drugs and explains the pharmacological improvements conferred by the addition of such NO-donor properties.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161209787315611
2009-02-01
2025-05-30
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161209787315611
Loading

  • Article Type:
    Research Article
Keyword(s): cardiovascular drugs; multi-target drugs; Nitric oxide; pharmacodynamic hybrids
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test